In conversation with NDTV, Glenn Saldanha, CMD of Glenmark Pharmaceuticals, says that he is pleased with the Q3 performance of the company and that they have outperformed peers in the domestic market. However, he adds that a growth rate of 30 per cent in the domestic markets is not sustainable.
